Current Status
Not Enrolled
Get Started

Program Director

Jennifer G. Robinson, MD, MPH

Program Director

Raul D Santos, MD, MSc, PhD

Preventing Atherosclerotic Cardiovascular Disease in Patients with Diabetes Mellitus

The IAS recognizes that system-level improvements are needed in the prevention of ASCVD in patients with diabetes and that progress in CVD risk factor control is slowing. Based on US data, only 14% of patients meet targets for all A1C, BP, lipids, and nonsmoking status. 33-49% of patients still do not meet one or several targets for A1C, blood pressure, or lipids. This problem is exacerbated globally as even fewer meet these targets in many low-and middle-income countries.

The purpose of this video series are to provide a better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focused discussion on statins and newer diabetes drugs.

Each section is introducted by general lecture of the clinical prevalence and evidence. The panel will discuss the real world implications and provide practical implemtation advice.

Pre-activity information

This program is intended for health care professionals management or prevention of ASCVD and specifically those engaged in treating patients diabetes mellitus.

At the end of this activity the learner will have:

A better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focus on statins and newer diabetes drugs.


Jennifer G. Robinson MD, MPH

DisclosuresDate of Disclosures
Research grants to Institution: Acasti, Amarin, Amgen, Astra Zeneca, Esai, Esperion, Merck, Novartis, Novo-Nordisk, Regeneron, Sanofi, Takeda. 10-12-2019
Consultant: Amgen, Medicines Company, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi10-12-2019

Raul D Santos, MD, MSc, PhD

DisclosuresDate of Disclosures
Consulting/Speaking/Research activities from: Akcea, Amgen, AstraZeneca, Biolab, Esperion, Kowa, Merck, Novo-Nordisk, Pfizer, and Sanofi/Regeneron.10-12-2019

Peter Lansberg, MD, PhD

DisclosuresDate of Disclosures
Unpaid Steering Committee: Kaneka10-12-2019
Consultant/Advisory Board: Kaneka, Getz Pharma, Zora, Gendiag.10-12-2019
Speaker Bureau: Amgen, Sanofi, Pfizer, Astra-Zeneca, Merck Sharp & Dohme, Getz Pharma; Gendiag10-12-2019

Philip Barter, MBBS, PhD, FRACP

DisclosuresDate of Disclosures
Consultant/Advisory Board/Speaker Honorarium for Amgen, Pfizer and Sanofi-Regeneron10-12-2019

Khalid Al-Rasadi, MD

DisclosuresDate of Disclosures
Honoraria for Speakers Bureau: AstraZeneca, Sanofi, Pfizer, Abbott. Advisory Boards: Sanofi, Aegerion.10-12-2019

Dong Zhao, PhD

DisclosuresDate of Disclosures
Research Grants to Institutions: Astra-Zeneca, Amgen, Boehringer-Ingelheim, Pfizer10-12-2019

Peter Libby MD

DisclosuresDate of Disclosures
Grant/Research support: Novartis10-12-2019
Unpaid Consultant and/or Unpaid Steering or Executive Committee of Clinical Trials: Amgen, AstraZeneca, Esperion, GlaxoSmithKline, Kowa, Merck, Novartis, Pfizer, Sanofi-Aventis-Regeneron10-12-2019
Scientific Advisory Board: IFM, Medimmune, DalCor, Amgen, Novartis, Corvidia, Olatec, Xbiotech10-12-2019
Dr. Libby declines all personal compensation from pharma or device companies.10-12-2019

Staff Disclosures

Nothing to disclose.

The International Atherosclerosis Society would like to thank Upjohn, a division of Pfizer, for their sponsorship of this education initiative.

Role of Newer Type 2 Mellitus Drugs (SLGT2 and GLP-1 RA) for ASCVD Prevention

See more...

Residual Dyslipidemia in Type 2 Mellitus and Implications for Atherosclerotic Cardiovascular Disease Prevention

See more...

Statins, LDL-C Lowering, and Prevention of Atherosclerotic Cardiovascular Disease in Diabetes Mellitus

See more...

Natural History and Atherosclerotic Cardiovascular Disease Risk Stratification in Diabetes Mellitus

See more...